-- 最高医療責任者のペン・ルー氏は、2026年5月1日にファーバリス（PHVS）の株式14,166株を427,419ドルで売却しました。SECへのフォーム4の提出後、ルー氏は同社の普通株式合計66,083株を保有しており、そのうち66,083株は直接保有しています。 SEC提出書類：https://www.sec.gov/Archives/edgar/data/1830487/000119312526206273/xslF345X05/ownership.xml
Price: $29.94, Change: $-0.08, Percent Change: -0.27%
Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml